Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short Course ADT, Hypofractionated Pelvic Radiation and Brachytherapy Boost for High-Risk Prostate Cancer
NCT05100472Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2021
- Primary completion
- Oct 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bicalutamide, leuprolide in prostate cancer (PCa), sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2021; status: active, not recruiting.
02
Drugs
bicalutamideleuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05100472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05100472.